BMY Bristol-Myers Squibb Company

Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2017 Global Healthcare Conference on Wednesday, December 6, 2017, in New York. Murdo Gordon, chief commercial officer, will answer questions about the company at 2:55 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

EN
30/11/2017

Underlying

BMYBristol-Myers Squibb Company

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bristol-Myers Squibb Company

BMY BRISTOL-MYERS SQUIBB COMPANY
11/26/25 November 26, 2025 1 EN
EUR 154.75
BMY Bristol-Myers S...

Bristol-Myers Squibb Company: Update to credit analysis

Our credit view of this issuer reflects its large scale and solid presence in the global pharmaceutical market, against its significant patent expirations.

BMY BRISTOL-MYERS SQUIBB COMPANY
11/25/25 November 25, 2025 1 EN
BMY Bristol-Myers S...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 19 November 2025 in which we reassessed the appropriateness of the ratings in ...

BMY BRISTOL-MYERS SQUIBB COMPANY
11/22/25 November 22, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.99
SNYN SANOFI S.A. ADS
NOVA Novo Nordisk A/... ... (+11)

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

SNYN SANOFI S.A. ADS
NOVA NOVO NORDISK A/S ADS
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
NVS.. NOVARTIS AG ADS
ABBV ABBVIE INC.
BAYA BAYER AG ADS
AZN ASTRAZENECA PLC ADS
GSK GSK PLC
11/19/25 November 19, 2025 1 EN
Gary Brode
  • Gary Brode
LLY ELI LILLY AND COMPANY
BMY BRISTOL-MYERS SQUIBB COMPANY
PFE PFIZER INC.
10/06/25 October 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch